Drug Profile
VERU 112
Alternative Names: VERU-112Latest Information Update: 28 Dec 2021
Price :
$50
*
At a glance
- Originator Veru Healthcare
- Class Antigouts; Antirheumatics; Small molecules
- Mechanism of Action Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Familial Mediterranean fever; Gout
Most Recent Events
- 28 Dec 2021 No recent reports of development identified for research development in Familial-Mediterranean-fever in USA (PO)
- 28 Dec 2021 No recent reports of development identified for research development in Gout in USA (PO)
- 03 Nov 2017 Early research in Familial Mediterranean fever in USA (PO) before November 2017 (Veru Healthcare pipeline, November 2017)